The company said that since it reported its Q2 2020 financial results, organic testing volumes for its base business have recovered faster than expected.
State agencies will no longer use Quest for testing following its failure to report to the state results from roughly 75,000 SARS-CoV-2 tests in a timely manner.
While the market ditched shares of many other diagnostics firms, analysts said the reaction was overblown, particularly in the case of Quidel and molecular diagnostics players.
Quest and its foundation will provide testing services, educational programs, partnerships, and financial support estimated to be worth more than $100 million.
A Quest executive said the company aims to add value by making testing more convenient for Anthem patients and using lab data to better manage their health.
Saying pooled testing for coronavirus was not for diagnostic purposes, Cigna had said it wouldn't reimburse for the method, but it plans to change its policy.
The companies said they will collaborate on driving operational improvements, creating price transparency, and improving consumer engagement and outcomes.
